Monday is a $1.25 million payday for Inspire Pharmaceuticals (Nasdaq: ISPH).

The Durham-based company says its Japan-based partner Santen Pharmaceutical has received regulatory approval to sell Inspire’s dry-eye treatment drug Diquas in than country.

As a result, Inspire will receive a $1.25 million milestone payment plus future royalties.

Get the latest news alerts: Follow LTW at Twitter.